What are the first‑line pharmacologic options and dosing regimens for treating attention‑deficit/hyperactivity disorder in adults without contraindications such as uncontrolled hypertension, serious cardiac disease, psychosis, or active substance use disorder?

First-Line ADHD Medications for Adults: Prescribing Guide

Stimulants—specifically methylphenidate or lisdexamfetamine—are the first-line pharmacological treatment for adults with ADHD, with methylphenidate typically preferred as the initial choice. 1, 2

Stimulant Options and Dosing

Methylphenidate (First Choice)

Starting dose: 5 mg once or twice daily
Dose range: 5-60 mg/day (typically divided doses for immediate-release; once daily for extended-release)
Titration: Increase weekly by 5-10 mg increments based on response

Methylphenidate formulations fall into three categories by duration:

• 12-hour formulations (extended-release): Provide all-day coverage, preferred for most adults needing consistent symptom control throughout work and evening hours 1
• 8-hour formulations (intermediate-acting): Useful when shorter duration needed
• 3-4 hour formulations (immediate-release): Rapid onset, allows flexible dosing but requires multiple daily doses 1

Key advantage: Rapid onset of therapeutic effects (within hours), allowing quick assessment of efficacy 3

Lisdexamfetamine (Alternative First-Line)

Starting dose: 30 mg once daily in the morning
Dose range: 30-70 mg once daily
Titration: Increase by 10-20 mg weekly

Duration: Approximately 12-13 hours due to prodrug formulation 1
Key advantage: Lower abuse potential compared to immediate-release amphetamines; smooth, sustained effect throughout the day 1

Monitoring Requirements

Monitor at baseline and regularly during treatment:

• Blood pressure and pulse (stimulants increase both) 3
• Weight and appetite (decreased appetite is common) 3
• Sleep patterns (insomnia frequent; dose early in day to minimize) 3
• Cardiac symptoms (palpitations, chest pain—contraindicated in uncontrolled hypertension, serious cardiac disease) 4
• Psychiatric symptoms (mood changes, anxiety, psychosis) 5

Second-Line Options (When Stimulants Fail or Are Contraindicated)

Atomoxetine

Starting dose: 40 mg once daily
Target dose: 80-100 mg/day (can divide into twice-daily dosing)
Maximum: 100 mg/day

Critical timing note: Requires 6-12 weeks to achieve full therapeutic effect—not appropriate when rapid symptom control needed 3

Advantages:

• Non-controlled substance (no abuse potential)
• "Around-the-clock" symptom coverage
• Preferred when comorbid substance use disorder present 3

Monitoring: Suicidality (especially early treatment), pulse, clinical worsening 3

Clinical Decision Algorithm

1. Start with methylphenidate (immediate or extended-release based on coverage needs)

   • If inadequate response after adequate trial (appropriate dose for 4-6 weeks): Switch to lisdexamfetamine 3

2. If lisdexamfetamine fails: Consider atomoxetine as second-line 3

3. Special circumstances favoring non-stimulants first:

   • Active or recent substance use disorder
   • Significant anxiety about controlled substances
   • Severe insomnia unresponsive to sleep hygiene
   • Uncontrolled hypertension or cardiac disease (absolute contraindication to stimulants) 4

Common Pitfalls to Avoid

• Underdosing stimulants: Many adults require higher end of dose ranges; titrate adequately before declaring treatment failure
• Stopping too soon: Allow 4-6 weeks at therapeutic dose before switching medications
• Ignoring cardiovascular screening: Always assess for cardiac history, uncontrolled hypertension, arrhythmias before prescribing stimulants 4
• Missing comorbid conditions: Anxiety, depression, and substance use disorders are extremely common and may require concurrent treatment 6
• Expecting immediate results with atomoxetine: This medication requires patience—effects emerge over 6-12 weeks 3

Important Caveats

The evidence base primarily derives from pediatric populations 3, 7, though adult-specific data increasingly supports similar efficacy 5, 1, 2, 8, 6. One meta-analysis suggests immediate-release methylphenidate may have superior efficacy compared to longer-acting formulations in adults 9, though this contradicts practical considerations favoring extended-release for consistent all-day coverage 1, 2.

Stimulants are controlled substances with abuse potential—document appropriate assessment and monitoring 3. However, when prescribed appropriately, they offer the largest effect sizes for ADHD symptom reduction and rapid therapeutic benefit 3.

Pharmacological treatment should integrate with psychoeducation and behavioral interventions, though medication provides the most robust symptom improvement 3, 6.